The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | -11,168 |
| Stock-based compensation expense | 1,267 |
| Non-cash lease expense | 88 |
| Fair value adjustment on common warrants | -915 |
| Depreciation | 2 |
| Accounts receivable | 96 |
| Inventory | 189 |
| Prepaid expenses | -90 |
| Other current assets | 0 |
| Accounts payable | 213 |
| Accrued expenses | -265 |
| Net cash used in operating activities | -10,973 |
| Purchase of property and equipment | 2 |
| Net cash used in investing activities | -2 |
| Proceeds from common stock and pre-funded common stock warrants | 12,102 |
| Costs of issuance of common stock upon private placement | 1,299 |
| Proceeds from exercise of common stock warrants | 25 |
| Proceeds from exercise of stock options | 17 |
| Net cash provided by financing activities | 10,845 |
| Change in cash and cash equivalents | -130 |
| Cash and cash equivalents, beginning of period | 7,154 |
| Cash and cash equivalents, end of period | 7,024 |
RenovoRx, Inc. (RNXT)
RenovoRx, Inc. (RNXT)